Las Vegas—In January 2018, Harvard Pilgrim Health Care announced that it had negotiated a value-based contract (VBC) focused on both short- and long-term outcomes for Spark Therapeutics’ novel gene therapy for inherited retinal disease, voretigene neparvovec-rzyl (Luxturna).
The agreement ties the health plan’s level of payment for the genetic therapy to measured improvements in full-field light sensitivity threshold testing scores at a 30- to 90-day interval, and